In Oregon, the incidence of meningococcal disease has increased substantially, more than doubling from 2.2 cases per 100,000 persons in 1992 to 4.6 per 100,000 in 1994--the highest incidence in Oregon since 1943. This incidence was almost fivefold higher than recent estimates for the United States during 1989-1991 (approximately one case per 100,000 persons annually) (1). This report describes ...

Invasive meningococcal disease is a serious life-threatening infection. Skin rash is present in about half of the patients with meningococcal infection. However it could be easily missed if no thorough cutaneous examination is performed. Herein, we present a patient with invasive meningococcal serogroup B infection with diffuse cutaneous purplish rash and ecchymoses, suggestive of purpura fulmi...

Neisseria meningitidis can be considered a continually emerging pathogen due to its genetic mutability and dynamic epidemiology. Currently, six serogroups (A, B, C, W-135, X and Y) are important to global disease epidemiology. Until 2000, serogroup W-135 was rare worldwide. Hajj-associated W-135 outbreaks caused by a virulent ST-11 strain in 2000 and 2001 raised concerns about widespread epidem...

Meningococcal diseases are serious threats to global health, and new vaccines specifically tailored to meet the age-related needs of various geographical areas are required. This paper focuses on the meningococcal conjugate vaccines developed by GSK Biologicals. Two combined conjugate vaccines were developed to help protect infants and young children in countries where the incidence of meningoc...

The effectiveness of a vaccine is determined not only by the immunogenicity of its components, but especially by how widely it covers the disease-causing strains circulating in a given region. Because vaccine coverage varies over time, this study aimed to detect possible changes that could affect vaccine protection during a specific period in a southern European region. The 4CMenB vaccine is li...

This paper describes a sudden increase of meningococcal notifications in the Australian Capital Territory within a 3 month period, and the public health strategies used to manage it. There were 15 cases of meningococcal disease notified to the Communicable Disease Control (CDC) section, Australian Capital Territory Health (ACT Health), between 6 November 2003 and 5 February 2004. This was much ...

Serogroup B is the only major disease-associated capsular group of Neisseria meningitidis for which no protein-polysaccharide conjugate vaccine is available. This has led to the development of multi-component protein-based vaccines that target serogroup B invasive meningococcal disease (IMD), including Bexsero®, which was implemented for UK infants in 2015, and Trumenba®. Given the diversity of...

Published recommendations of the Advisory Committee on Immunization Practices (ACIP) of the Centers for Disease Control and Prevention, which carry the approval of the Secretary of Health and Human Services, provide guidance on how licensed vaccines should be used. Professional organizations such as the American Academy of Family Physicians and the American Academy of Pediatrics (AAP) also deve...

conclusions these results show the usefulness of proteome analysis in successful identification of the common proteins between n. lactamica strains and nmb. this proteomics analysis is the starting point in the path of knowledge development about whole proteome profiles of n. lactamica strains. objectives the main aims of this study were to determine whole proteome profiles of n. lactamica stra...